| 张 莹.普瑞巴林联合重组人干扰素α-2b对带状疱疹后遗神经痛的影响[J].中国烧伤创疡杂志,2020,(1):55~58. |
| DOI： |
| 中文关键词: 带状疱疹后遗神经痛 普瑞巴林 重组人干扰素α-2b 疼痛评分 疗效 炎症反应 |
| 英文关键词:Postherpetic neuralgia Pregabalin Recombinant human interferon α-2b Pain score Efficacy Inflammatory response |
| 基金项目: |
|
| 摘要点击次数: 1938 |
| 全文下载次数: 4291 |
| 中文摘要: |
| 【摘要】目的 研究普瑞巴林联合重组人干扰素α-2b治疗带状疱疹后遗神经痛（postherpetic neuralgia，PHN）的临床疗效。方法 选取2016年1月至2018年12月咸宁市中心医院收治的92例PHN患者作为研究对象，并按照随机数表法将其随机分为试验组（46例）和对照组（46例），其中对照组患者予以口服普瑞巴林治疗，试验组患者在口服普瑞巴林的基础上肌肉注射重组人干扰素α-2b，对比观察两组患者的临床疗效及血清白细胞介素6（IL-6）、白细胞介素10（IL-10）水平的变化情况，并采用视觉模拟评分法(visual analogue score，VAS)评估患者治疗前后的疼痛程度。结果 治疗后，两组患者疼痛程度均逐渐减轻（F=113.518，P=0.000），且治疗第3、5、10、30天试验组患者VAS评分均显著低于对照组（t=2.525、7.172、6.237、6.000，P=0.013、0.000、0.000、0.000），差异具有统计学意义；治疗第30天，试验组患者治疗总有效率为86.96%，明显高于对照组患者的治疗总有效率69.57%（Mann-Whitney U=759.500，Z=-2.462，P=0.014），差异具有统计学意义；治疗第30天，两组患者血清IL-6水平均降低，且试验组显著低于对照组（t=27.773，P=0.000），血清IL-10水平均升高，且试验组显著高于对照组（t=13.607，P=0.000），差异具有统计学意义。结论 普瑞巴林联合重组人干扰素α-2b治疗带状疱疹后遗神经痛，可有效减轻患者疼痛，疗效显著，值得临床推广应用。 |
| 英文摘要: |
| 【Abstract】Objective To study the clinical effect of pregabalin combined with recombinant human interferon α-2b on postherpetic neuralgia (PHN). Methods Ninety-two patients with postherpetic neuralgia, admitted to Xianning Central Hospital from January 2016 to December 2018, were selected as subjects and then divided, according to random number table, into an experiment group (46 cases) and a control group (46 cases). Patients in the control group took pregabalin orally. In addition to oral administration of pregabalin, patients in the experiment group were also injected with recombinant human interferon α-2b. The clinical effect and changes of serum interleukin 6 level (IL-6) and interleukin 10 (IL-10) level in the two groups were compared and observed. Visual analogue score (VAS) was used to evaluate patients’ pain degree before and after treatment. Results After treatment, patients’ pain gradually alleviated (F = 113.518, P = 0.000) in the two groups. On day 3, 5, 10 and 30, the VAS scores in the experiment group were significantly lower than those in the control group (t = 2.525, 7.172 , 6.237, 6.000, P = 0.013, 0.000, 0.000, 0.000) and the results of comparison showed statistically significant difference; On day 30, the total effective rate in the experiment group was 86.96%, much higher than 69.57% in the control group(Mann-Whitney U = 759.500, Z = -2.462, P = 0.014) and the results of comparison showed statistically significant difference; On day 30, the serum IL-6 level in the two groups decreased, and its level in the experiment group was significantly lower than that in the control group (t = 27.773, P = 0.000) ; the serum IL-10 level in the two groups increased, and its level in the experiment group was significantly higher than that in the control group (t = 13.607, P = 0.000), and the results of comparison showed statistically significant difference. Conclusion Pregabalin combined with recombinant human interferon α-2b in the treatment of postherpetic neuralgia can alleviate patients' pain. It deserves to be promoted in clinical practice due to its good clinical efficacy. |
|
|
|
|
